| Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. | |
| | |
MedLine Citation:
|
PMID: 17276373 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: HHV-6 replication requires complex and poorly understood interactions between viral and cellular factors. OBJECTIVES: Several natural compounds or broad-acting pharmacological agents were studied in an attempt to discover new targets for anti-HHV-6 therapy. STUDY DESIGN: The antiviral activity was determined in human T-lymphoblasts, using HHV-6A (GS)-infected HSB-2 cells, HHV-6B (Z29)-infected MOLT-3 cells and HHV- 6B (HST)-infected MT4 cells. Virus replication was measured by CPE and qPCR assay. Foscarnet was included as the reference compound. RESULTS: Among the 15 natural compounds tested, only 'red marine algae' (an extract rich in sulfated polysaccharides) exhibited strong activity when added during virus adsorption. Among the broad-acting pharmacological agents, chloroquine, artemisinin, hypericin, ribavirin, resveratrol and glycyrrhizic acid were all inactive. Amantadine produced a reproducible inhibition of HHV-6 replication, albeit at relatively high concentrations. Except for lamotrigine, which was moderately active against HHV-6B, several antiepileptic drugs were shown to have no activity. We included several compounds which we previously described as potent HHV-6 inhibitors, i.e., the non-nucleoside inhibitor CMV423 and the acyclic nucleoside phosphonate analogues cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-3-deazaadenine. The latter compound exhibited remarkable anti-HHV-6 activity. CONCLUSION: Further optimization of compounds belonging to diverse classes of antiherpetic agents, for their specific action against HHV-6, is warranted. |
| | |
Authors:
|
Lieve Naesens; Pascale Bonnafous; Henri Agut; Erik De Clercq |
Related Documents
:
|
18443553 - Determination of lamivudine-resistant variants of hepatitis b virus by denaturing gradi... 19290033 - Hiv-1 genotypic drug resistance interpretation rules - 2009 spanish guidelines. 10963283 - The proton-pump inhibitors: similarities and differences. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology Volume: 37 Suppl 1 ISSN: 1386-6532 ISO Abbreviation: J. Clin. Virol. Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2007-02-05 Completed Date: 2007-08-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815671 Medline TA: J Clin Virol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: S69-75 Citation Subset: IM |
Affiliation:
|
Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium. lieve.naesens@rega.kuleuven.be |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antiviral Agents
/
pharmacology* Cell Line Cytopathogenic Effect, Viral / drug effects DNA, Viral / biosynthesis Herpesvirus 6, Human / drug effects*, physiology Humans Lymphocytes / virology* Polymerase Chain Reaction Virus Replication / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/DNA, Viral |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Human herpesvirus 6B inhibits cell proliferation by a p53-independent pathway.
Next Document: HHV-6 DNA in peripheral blood mononuclear cells after liver transplantation.